Table 1.
Demographic data and CSF-biomarker levels of the included subjects at risk for FAD. Demographic characteristics of the mutation carrier group and the non-carrier group at the time of baseline CSF sampling. Age, expected years to symptom onset, and levels of Aβ42, YKL-40, and neurogranin are presented as mean values ± standard deviation. *Levels of t-tau and p-tau are presented as median with range, due to lack of normal distribution of the data. One of the mutation carriers is an APOE e2/e4 heterozygote and is included in the table as both an ɛ2 and an ɛ4 carrier. N, number; NS, not significant
| Mutation carriers | Non-carriers | p | |
| (n = 14) | (n = 17) | ||
| Age | 43±10 | 46±12 | NS |
| Expected years to symptom onset | –12±10 | –9±12 | NS |
| Gender (Male/Female) | 11/3 | 10/7 | NS |
| APOEɛ4 carriers (n) | 8 | 7 | NS |
| APOEɛ2 carriers (n) | 1 | 3 | NS |
| Aβ42 (pg/mL) | 221±138 | 626±277 | p < 0.0001 |
| t-tau* (pg/mL) | 472 (169–937) | 241 (122–537) | p = 0.01 |
| p-tau* (pg/mL) | 58 (28–104) | 36 (19–76) | p = 0.06 |
| YKL-40 (ng/mL) | 98±33 | 91±38 | NS |
| Neurogranin (pg/mL) | 252±90 | 215±84 | NS |